Ilaria Attili - Concepedia

Author

Ilaria Attili

Istituti di Ricovero e Cura a Carattere Scientifico ORCID

Also Known As

I. Attili, Ilaria Attili

129

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere Scientifico Istituto Oncologico Veneto European Institute of Oncology University of Padua University of Milan

About

Ilaria Attili is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in lung cancer, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	289
2	Health Sciences	2	2	26
3	Public Health	2	2	52
4	Epidemiology	2	2	52
5	Cell Biology	1	1	77

Ilaria Attili

Publications

749

Citations

H-Index

Page 1

	Year	Citations
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors Alberto Pavan, Lorenzo Calvetti, Alessandro Dal Maso, The Oncologist	2019	224
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes Laura Bonanno, Alberto Pavan, Maria Vittoria Dieci, European Journal of Cancer Cancer ImmunosurveillanceImmune MicroenvironmentPd-l1 ExpressionImmunologyBronchial Neoplasm	2018	112
Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis Niki Karachaliou, Imane Chaib, Andrés F. Cardona, EBioMedicine Common Co-activationMedicinePathologyBronchial NeoplasmCancer Biology	2018	77
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome Alberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti, Translational Lung Cancer Research	2021	43
Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations Antonio Passaro, Ilaria Attili, Alessandra Rappa, Cancers	2021	43
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer Elisabetta Zulato, Ilaria Attili, Alberto Pavan, British Journal of Cancer	2020	41
Fears and Perception of the Impact of COVID-19 on Patients With Lung Cancer: A Mono-Institutional Survey Chiara Catania, Gianluca Spitaleri, Ester Del Signore, Frontiers in Oncology Italian GovernmentEpidemiology Of CancerPopulation Health SciencesCovid-19 EpidemiologyCovid-19	2020	27
Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO Model Filippo de Marinis, Ilaria Attili, Stefania Morganti, Frontiers in Oncology World Health OrganizationElderly PatientsCancer ManagementCovid-19 EpidemiologyCovid-19	2020	25
Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features Antonio Passaro, Silvia Novello, Diana Giannarelli, Cancers	2021	24
Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors Elisabetta Zulato, Paola Del Bianco, Giorgia Nardo, British Journal of Cancer Discussion Liquid BiopsyImmunologyPathologyImmunotherapyOncology	2022	22

Page 1